跳至主要内容
临床试验/NCT06450834
NCT06450834Enrolling By Invitation不适用

Prospective, Propensity-score Matched Cohort Analysis Evaluating the Use of Ostene Bone Hemostasis Material During Thoracolumbar Decompression, Instrumentation, and Fusion Using a Validated Intraoperative Bleeding Scale

University of Maryland, Baltimore2 个研究点 分布在 1 个国家目标入组 173 人开始时间: 2025年1月17日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
173
试验地点
2
主要终点
Intraoperative blood transfusion

研究概览

简要总结

In spine surgery, it is important to try to minimize bleeding. In particular, spine surgery often involves inserting hardware into bone, and/or removing bone in the spine. Because the bone in the spine contains blood vessels, there can often be bleeding from the bone itself that is difficult to stop completely. One way to stop bone bleeding is through the use of wax-like materials, which plug the bleeding bone and act as a physical barrier to stop bleeding. One example is Ostene bone hemostasis material, which has the advantage of being "water soluble", meaning it will dissolve naturally over time. The purpose of this study is to evaluate how well Ostene does at decreasing bleeding, by using a recognized scale called the validated intraoperative bleeding severity scale, abbreviated as "VIBe". In this study, the investigators will record the bleeding severity throughout multiple time points in surgery using this scale, and then the investigators will compare the measurements to patients in the past who did not receive Ostene. Overall, this research will help measure how well Ostene decreases bleeding.

详细描述

  • Patients will be screened prior to surgery for inclusion and exclusion criteria.

  • If eligible, patients will be approached in the preoperative area or clinic location to consent or refuse participation in the study.

  • Baseline characteristics will be collected via a combination of patient preoperative survey and manual chart review.

  • Patients will undergo the normal surgical standard of care, receiving Ostene intraoperatively as determined appropriate by the attending spine surgeon during the procedure.

  • It is anticipated that Ostene will be used specifically during the bony work/laminectomy phase preceding decompression. Of note, this material is now considered standard of care by our principal investigator and would be used regardless of study participation.

  • Other hemostatic agents will be used according to the typical standard of care.

  • A trained research coordinator will be present to determine VIBe scores during 6 key surgical phases: 1) exposure, 2) bony work/laminectomy, 3) decompression, 4) instrumentation, 5) fusion, and 6) closure. Agreement will be obtained from the operating surgeon.

  • For all phases, the maximum VIBe score during each phase will be recorded.

  • Surgical information will be documented from the operative note.

  • Patients will receive the normal standard of care postoperatively including measure(s) of their hemoglobin/hematocrit and postoperative drain output.

  • Data on postoperative outcomes/complications will be collected from the electronic medical record.

  • A propensity-score matched cohort analysis will be constructed to compare patients who received Ostene to patients who did not receive Ostene (will use data from past study conducted from 2021-April 2023 to construct matched control cohort).

  • There will be no group assignment in this study

  • There will be no placebo group or randomization

  • Patient data from a past study will be used as a control comparator

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 88 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients 18 to 88 years old
  • Elective thoracolumbar decompression, instrumentation, and fusion procedure
  • Open, posterior approach
  • Patients included for analysis in a related prior study which had enrollment criteria congruent with the current study

排除标准

  • Indication for trauma, tumor, or suspected/confirmed infection
  • Emergent triage status
  • Anterior or lateral approach
  • Minimally invasive approach

研究组 & 干预措施

Ostene

Patients who received Ostene during their thoracolumbar spine surgery

干预措施: Ostene (Device)

No Ostene

Propensity score matched cohort from previous study that did not receive Ostene during their spine surgery

结局指标

主要结局

Intraoperative blood transfusion

时间窗: Intraoperative

binary and number of units

postoperative blood transfusion

时间窗: 3 days

binary and number of units

次要结局

  • 3 days before surgery of preoperative hemoglobin/hematocrit(3 days)
  • days after surgery of postoperative hemoglobin/hematocrit(3 days)
  • length of stay(From the date of surgery until discharge up to 1 year)
  • cost(From the date of surgery until discharge up to 1 year)
  • preoperative hemoglobin/hematocrit(Immediately preoperative)
  • postoperative drain output(From the first day postoperatively then measured daily, until the patient is discharged, up to 1 year)
  • Presence of Deep Vein Thrombosis(From the date of surgery until 1 year follow up appointment)
  • Presence of Pulmonary Embolism(From the date of surgery until 1 year follow up appointment)
  • Presence of postoperative complication requiring medical intervention(From the date of surgery until 1 year follow up appointment)
  • 30-day readmissions(readmission within 30 days)
  • 30-day reoperations(reoperation within 30 days)
  • postoperative hemoglobin/hematocrit(3 days)
  • 30-day emergency department visits(ED visits within 30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Steven Ludwig

Professor of Orthopaedics

University of Maryland, Baltimore

研究点 (2)

Loading locations...

相似试验